Bell Potter analyst Thomas Wakim maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$335.00. The company’s shares closed today at $161.00. Leverage the ...
In a report released today, Derek Jellinek from Morgans maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$329.26. The company’s shares closed today at $161.00.
Revenue at CSL's Seqirus vaccine unit fell 9% to $1.66 billion in the half-year ended December 31, 2024. CEO Paul McKenzie said post-COVID apathy among 18-to-64-year-olds in the U.S., as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback